Clinical impact of COVID-19 on patients with choroidal neovascularization on intravitreal anti-VEGF therapy

Eye (Lond). 2022 May;36(5):1113-1114. doi: 10.1038/s41433-021-01698-5. Epub 2021 Jul 29.

Authors

Eleftherios I Agorogiannis^{1

2}, Deena Maleedy³, Navid Hakim³, David McDaid³, Laura Silver³, Savita Madhusudhan³, Nicholas A V Beare³

Affiliations

¹ St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, UK. eleftherios.agorogiannis@gmail.com.
² Moorfields Eye Hospital, London, UK. eleftherios.agorogiannis@gmail.com.
³ St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, UK.

No abstract available

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Bevacizumab / therapeutic use
COVID-19*
Choroidal Neovascularization* / drug therapy
Humans
Intravitreal Injections
Ranibizumab / therapeutic use

Substances

Angiogenesis Inhibitors
Bevacizumab
Ranibizumab